DiaMedica’s lead clinical stage product, DM199, is a recombinant human tissue kallikrien (rhKLK-1) protein designed to treat vascular and metabolic diseases.
Acute Vascular Disease
A variety of catastrophic medical events such as a heart attack, acute kidney failure or stroke are a result of sudden reduced blood flow (ischemia), and endothelial dysfunction, which can lead to damaging inflammation and hypoxia at the cellular level. These events can begin from a variety of factors such as blood clot formation, sudden low blood pressure or trauma.
Metabolic syndrome is a disorder of energy utilization and storage. One quarter of the world’s adult population has metabolic syndrome. It manifests when at least three metabolic risk factors are found in a single individual. These metabolic factors include abdominal fat, insulin resistance, hypertension (high blood pressure), high serum triglycerides, and low high-density cholesterol (HDL) levels. Metabolic syndrome is not a disease itself, but people with metabolic syndrome are much more likely to develop cardiovascular disease, stroke, or type 2 diabetes.